Meta Information
ID:citicoline
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/intervention/levodopa
Target name:
Levodopa
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Citicoline increases dopamine synthesis and receptor density in the brain, which can significantly amplify the effects and side effects (like dyskinesia) of Levodopa, a medication for Parkinson's disease.
Actionable advice:
These should not be combined without explicit medical supervision; dose adjustments of Levodopa are likely required.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
the levodopa-saving effect of citicoline could be used to decrease the incidence of side effects and retard the loss of efficacy of levodopa in long-term treatment
Label source:
Primary literature: https://pubmed.ncbi.nlm.nih.gov/2289218/
Action type:
avoid
Target id:
/class/dopaminergic-agents
Target name:
Dopaminergic Medications
Severity:
moderate
Interaction type:
synergistic
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
By increasing brain dopamine levels, Citicoline can enhance the effects and potential side effects of other medications that act on the dopamine system, such as dopamine agonists or MAO-B inhibitors.
Actionable advice:
This is best used with caution and medical supervision when taking any dopaminergic medication for conditions like Parkinson's or Restless Legs Syndrome.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Thus, citicoline has been experimentally shown to increase norepinephrine and dopamine levels in the CNS.
Label source:
PubMed: Methods and findings in experimental and clinical pharmacology (2006)
Source url:
Exact phrase from label:
Citicoline increases dopamine synthesis and inhibits dopamine uptake.
Label source:
PubMed: Clinical therapeutics (2021)
Source url:
Exact phrase from label:
In the same condition, citicoline and CAVAQ10 were also effective in reducing the gene expression of monoaminoxidase-B, involved in dopamine degradation. However, only citicoline demonstrated an ability to reduce dopamine levels.
Label source:
PubMed: Nutrients (2022)
Action type:
informational_none
Target id:
/class/cholinesterase-inhibitors
Target name:
Cholinesterase Inhibitors
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Both Citicoline (by providing a precursor) and cholinesterase inhibitors (e.g., donepezil, galantamine) increase acetylcholine levels, potentially leading to additive cognitive benefits or increased cholinergic side effects like nausea or diarrhea.
Actionable advice:
These are best combined only under medical supervision, as it may increase the risk of cholinergic side effects.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
citicoline is safe and effective in vascular cognitive disorders and also in neurodegenerative disorders such as Alzheimer's disease when associated with cholinesterase inhibitors
Label source:
Primary literature: https://www.neuroscigroup.us/articles/AADC-1-104.php
Action type:
informational_none
Target id:
/class/choline-precursors
Target name:
Other Choline Supplements
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combining multiple high-dose choline sources (e.g., Alpha-GPC, Choline Bitartrate) can lead to an excessive choline load, increasing the risk of side effects such as digestive upset, fishy body odor, and low blood pressure.
Actionable advice:
High doses of multiple choline supplements are best not taken concurrently; choosing one or using them under guidance is a good idea.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Exact phrase from label:
citicoline is a superior form of choline
Label source:
Primary literature: https://pmc.ncbi.nlm.nih.gov/articles/PMC6683073/
Action type:
avoid
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
The safety of citicoline supplementation during pregnancy has not been established through clinical research.
Actionable advice:
Citicoline should be avoided during pregnancy due to a lack of safety data.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
It is not known if or how citicoline could affect pregnancy or harm a fetus.
Label source:
Anecdotal: WebMD
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is unknown if citicoline or its metabolites pass into breast milk, and its safety for a nursing infant has not been established.
Actionable advice:
Citicoline should be avoided while breastfeeding due to a lack of safety data.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
It is not known if citicoline passes into breast milk.
Label source:
Anecdotal: WebMD
Action type:
avoid
Target id:
/circadian/wake
Target name:
Waking Up
Severity:
minor
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
null
Hours after target:
4
Description:
Taking Citicoline in the morning may align with its potential to support alertness and cognitive function throughout the day.
Actionable advice:
Citicoline is generally best taken in the morning or early afternoon to support daily cognitive demands.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Citicoline may prove effective in treating age-related cognitive decline that may be the precursor of dementia.
Label source:
PubMed: Citicoline improves verbal memory in aging. (PMID 8624220)
Action type:
informational_none
Target id:
/class/anticholinergic-medications
Target name:
Anticholinergic Medications
Severity:
minor
Interaction type:
diminishing
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Citicoline provides choline, a building block for the neurotransmitter acetylcholine, which may theoretically oppose the action of drugs designed to block acetylcholine's effects (e.g., for overactive bladder). [class-derived from: class_pharmacology]
Actionable advice:
Anticholinergic drugs may have reduced effectiveness, though this interaction is largely theoretical.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Exact phrase from label:
since it is formed by choline, it works for biosynthesis of acetylcholine
Label source:
Expert review: Citicoline provides choline for acetylcholine synthesis (mechanism established in CNS Drugs 2014; PMC3933742), while anticholinergic drugs block muscarinic acetylcholine receptors. Pharmacodynamic opposition at the acetylcholine receptor level is a class-level inference supported by the known mechanism of both agents.
Action type:
informational_none